


IMEL Biotherapeutics
Mitochondrial Rescue Therapy



Mitochondrial diseases

- Mitochondrial diseases are caused by mitochondrial dysfunction
- Primary mitochondrial dysfunction is caused by:
 - Acquired and/or inherited mutations in mitochondrial DNA – primary mitochondrial disease
 - Accumulation of mutations in mitochondrial DNA as a result of the aging process
- The ratio of healthy-vs-mutated mitochondrial DNA (heteroplasmy) correlates with disease severity

Mitochondrial disorders


1:5000 birth has primary mitochondrial disorder

> 100 primary/secondary mitochondrial diseases


Multisystemic disease presentations incl. central nervous system, eyes, skeletal muscle, heart, liver etc.

Age of onset from newborn to adulthood

Aging-related diseases, incl. neurodegenerative diseases, have mitochondrial involvement



Homoplasmy:
a single mitochondrial DNA type




Heteroplasmy:
two or more mitochondrial DNA types

-
- Seizures
 - Deafness
 - Liver failure
 - Renal disease
 - Hormone deficiencies
 - Myopathy
 - Stroke
 - Blindness
 - Cardiomyopathy
 - Diabetes
 - Enteropathy
 - Anemia
 - Neuropathy

IMEL's 1st product – autologous MirC stem cells (CD34+)

IMEL employs routine autologous stem cells transplantation method

 Adding a patented *ex vivo* step (03) to the routine transplantation process



Investors and Directors

PONTIFAX

Pontifax is a venture capital firm focusing on groundbreaking innovations in life sciences

Founded in 2004, Pontifax manages over \$775 M with a portfolio 80 companies

REMIGES
VENTURES

Remiges is a US-Japanese venture capital firm focused on biotechnology and pharmaceutical companies

Founded in 2014, Remiges is developing IP from the Japanese academia

IMEL's BoD members:

Dr. Silvia Noiman | Co-Founder, Chairperson and CEO:

A leading life sciences executive with over 25 years' experience in the healthcare Industry, including Eloxx (ELOX), cCAM, Predix (EPIX)


Mr. Tomer Kariv | Director:

The co-founder and CEO of Pontifax. Serves as an active board member of many of the funds' portfolio companies, assuming a special responsibility for strategic planning

Mr. Taro Inaba | Co-Founder and Director:

Founder & Managing Partner at Remiges Ventures with >29 years of business experience. Serves as a director of Koinobori and for many of Remiges' portfolio companies



 Suite 300, 303 Wyman St., Waltham, MA 02451

 +972 5 4450 6092

 dori@imelbiotx.com